If you only glanced at Haemonetics during early 2026, the mix of margin pressure, portfolio shifts, and debate over its plasma business hardly suggested an obvious winner. Investors who held Haemonetics from the start of the year are up 52.2%, including dividends. If you had been weighing those competing bull and bear cases back on 1 January, what in the available record might have justified accepting that kind of risk?
The move put Haemonetics in the middle of this trade. Scan 33 healthcare AI stocks for other companies exposed to it.
The Two Haemonetics Stories Investors Had To Weigh
The shares cost US$80.15 at the start of the period, and anyone looking at Haemonetics then was really choosing between two sharply different storylines about where the business might head next.
On the upbeat side, the bullish narrative argued that secular demand for blood management and recurring software revenue could support a fair value of US$108, a price implied by assumptions of technology driven share gains and profit margins reaching 19.1% within a few years.
The cautious view pointed to regulatory risk and plasma competition, with the bearish camp landing on a fair value of US$65.5 and worrying that reimbursement pressure and U.S. concentration might restrict earnings growth even if margins improved only to 15.2%.
What The Evidence Did To The Haemonetics Argument
The expanded CSL Plasma plan to roll out Haemonetics NexSys PCS with Persona PLUS across all U.S. centers by 2027 clearly leaned toward the optimistic plasma thesis. Q1 2027 revenue of US$339.4 million versus US$321.4 million in Q1 2026 supported that top line case, while net income slipped to US$33.0 million and net margin eased to 9.7%. As a result, the profitability piece remained unproven. Overall, the evidence cut both ways.
The episode turned on one assumption investors can test elsewhere. When a story hinges on higher margin potential, it can be helpful to track whether net margin actually rises alongside any new contract wins or product rollouts, rather than treating revenue alone as confirmation.
What Haemonetics Buyers Are Paying For After A 52% Run
Haemonetics now trades at US$122, after a 52.2% gain from the start of the year, and the selected Narrative’s Fair Value sits below that price. The Narrative treats today’s level as already baking in strong execution on plasma, hemostasis and interventional businesses.
For that to hold, a buyer has to believe free cash flow and margin quality stay resilient even if cost inflation or contract terms shift more than expected.
"The numbers imply the share price already embeds a continuation of recent revenue growth, margin expansion and cash generation, leaving limited room for disappointment if cost pressures or competitive responses intensify."
Not everyone reads the same price the same way. → See the lower figure this Narrative lands on, and how it gets there
Haemonetics And A Different Kind Of Hardware
Haemonetics pulls you into blood management, yet your map need not stop there.
Surgeons still need tools that turn those procedures into gentler operations for patients. One lesser known player builds robotic systems that let doctors work through tiny incisions.
Those robots started with military research into remote surgery for wounded soldiers. Today the focus is civilian care, helping hospitals perform minimally invasive procedures more consistently.
As more procedures shift from open cuts to guided instruments, that hardware maker leans on recurring demand for instruments, service and software. The interesting question is how that kind of repeat revenue might behave through tougher hospital budgets.
The case is on the record, with the assumptions it rests on. → See the Narrative that values this company 26% above its price
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com